[SCHEDULE 13G] Travere Therapeutics, Inc. Passive Investment Disclosure (>5%)
State Street reports 5.3% stake in Travere Therapeutics
Travere Therapeutics Inc received a major shareholder disclosure from State Street Corporation, which reported beneficial ownership of 4,756,666 Travere common shares, representing 5.3% of the class as of December 31, 2025.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Travere Therapeutics Inc received a major shareholder disclosure from State Street Corporation, which reported beneficial ownership of 4,756,666 Travere common shares, representing 5.3% of the class as of December 31, 2025.
State Street reports shared voting power over 4,485,757 shares and shared dispositive power over 4,756,666 shares, with no sole voting or dispositive authority. The position is certified as held in the ordinary course of business and not for changing or influencing control of Travere.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Travere Therapeutics (TVTX) shares does State Street beneficially own?
State Street Corporation reports beneficial ownership of 4,756,666 Travere Therapeutics common shares. This stake is disclosed in a Schedule 13G as of December 31, 2025, and reflects shares over which State Street and its subsidiaries have shared dispositive power under SEC beneficial ownership rules.
What percentage of Travere Therapeutics (TVTX) does State Street’s holding represent?
State Street Corporation’s position represents 5.3% of Travere Therapeutics’ common stock. This percentage is based on 4,756,666 shares reported as beneficially owned. Crossing the 5% threshold requires public disclosure of holdings under SEC rules through a Schedule 13G or Schedule 13D filing.
What voting and dispositive powers does State Street have over Travere (TVTX) shares?
State Street reports shared voting power over 4,485,757 shares and shared dispositive power over 4,756,666 shares. It reports no sole voting or sole dispositive power. These figures indicate control is exercised collectively through State Street and its listed asset management subsidiaries.
As of what date are State Street’s Travere (TVTX) holdings reported?
The Travere Therapeutics holdings are reported as of December 31, 2025. That date is the event triggering the beneficial ownership disclosure, meaning State Street’s 5.3% position met reporting thresholds on or before then under applicable SEC Schedule 13G regulations.
Does State Street indicate any intent to influence control of Travere Therapeutics (TVTX)?
State Street certifies the Travere shares were acquired and are held in the ordinary course of business. It further states they were not acquired and are not held for changing or influencing control of Travere or as part of any control-related transaction.
Which State Street affiliates are identified in connection with the Travere (TVTX) holdings?
The disclosure lists several State Street Global Advisors entities linked to the holding. These include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., each classified as an investment adviser.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
TRAVERE THERAPEUTICS INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
89422G107
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
89422G107
1
Names of Reporting Persons
STATE STREET CORPORATION
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
MASSACHUSETTS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,485,757.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,756,666.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,756,666.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
TRAVERE THERAPEUTICS INC
(b)
Address of issuer's principal executive offices:
3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO, CALIFORNIA, 92130
Item 2.
(a)
Name of person filing:
STATE STREET CORPORATION;
(b)
Address or principal business office or, if none, residence:
ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
(c)
Citizenship:
MA
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP No.:
89422G107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
4756666.00
(b)
Percent of class:
5.3 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
4,485,757
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
4,756,666
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
NOT APPLICABLE
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
NOT APPLICABLE
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
NOT APPLICABLE
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
